A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
AstraZeneca
Study ID
NCT07662213
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Elecoglipron — DRUG
    Elecoglipron is administered orally once daily.
  • Semaglutide — DRUG
    Semaglutide is administered orally once daily.

Study Details

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

Key Dates

Start date
Jul 6, 2026
Status verified
Jun 2026
Primary completion
May 23, 2028
Completion
May 23, 2028

Study Design

Enrollment
1,200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Elecoglipron
    Participants will receive elecoglipron dose XX mg administered orally once daily.
  • Active Comparator: Semaglutide
    Participants will receive semaglutide dose XX mg administered orally once daily.

Primary Outcome Measure

Change from baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline to Week 52 ]

Central Contacts

Locations (41)

FacilityCityStateZIPSite coordinators
Research SiteBirminghamAlabama35205-
Research SiteMesaArizona85213-
Research SitePhoenixArizona85016-
Research SiteTempeArizona85281-
Research SiteEncinitasCalifornia92024-
Research SiteGarden GroveCalifornia92844-
Research SiteLincolnCalifornia95648-
Research SiteLoma LindaCalifornia92350-
Research SitePomonaCalifornia91768-
Research SiteCrystal RiverFlorida34429-
Research SiteHollywoodFlorida33021-
Research SiteJacksonvilleFlorida32209-
Research SiteLeesburgFlorida34748-
Research SiteIdaho FallsIdaho83404-
Research SiteMelrose ParkIllinois60160-
Research SiteAmesIowa50010-
Research SiteWichitaKansas67226-
Research SiteBowling GreenKentucky42101-
Research SiteRockvilleMaryland20852-
Research SiteSouthfieldMichigan48076-
Research SiteJefferson CityMissouri65109-
Research SiteKansas CityMissouri64114-
Research SiteOmahaNebraska68114-
Research SiteHendersonNevada89052-
Research SiteLas VegasNevada89128-
Research SiteAlbuquerqueNew Mexico87112-
Research SiteDurhamNorth Carolina27701-
Research SiteMorehead CityNorth Carolina28557-
Research SiteStatesvilleNorth Carolina28625-
Research SiteWilmingtonNorth Carolina28403-
Research SiteColumbusOhio43215-
Research SiteYukonOklahoma73099-
Research SiteDallasTexas75390-
Research SiteSugar LandTexas77478-
Research SiteBountifulUtah84010-
Research SiteSalt Lake CityUtah84124-
Research SiteLeesburgVirginia20176-
Research SiteNorfolkVirginia23502-
Research SiteSeattleWashington98104-
Research SiteSeattleWashington98105-
Research SiteMorgantownWest Virginia26505-

Find similar trials in Birmingham, AL

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Research Site· Birmingham, ALResearch Site· Mesa, AZResearch Site· Phoenix, AZResearch Site· Tempe, AZResearch Site· Encinitas, CAResearch Site· Garden Grove, CA

Related Studies